Rhenman & Partners Asset Management Ab Arcellx, Inc. Transaction History
Rhenman & Partners Asset Management Ab
- $1.2 Billion
- Q3 2024
A detailed history of Rhenman & Partners Asset Management Ab transactions in Arcellx, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 32,000 shares of ACLX stock, worth $2.48 Million. This represents 0.22% of its overall portfolio holdings.
Number of Shares
32,000Holding current value
$2.48 Million% of portfolio
0.22%Shares
1 transactions
Others Institutions Holding ACLX
# of Institutions
204Shares Held
44.2MCall Options Held
2.23MPut Options Held
907K-
Paradigm Biocapital Advisors LP New York, NY4MShares$310 Million12.04% of portfolio
-
Perceptive Advisors LLC New York, NY3.89MShares$302 Million8.48% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$291 Million23.89% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$273 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.46MShares$191 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3.4B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...